Sage Details 40% Job Cuts While Zurzuvae’s Future In MDD Remains Unclear

Reorganization Puts Earlier-Stage Programs On Hold

 
• By Mandy Jackson

Zurzuvae will launch this year for postpartum depression, but US FDA rejection of the drug in major depressive disorder spurred Sage to cut R&D programs and jobs as it and partner Biogen evaluate next steps in MDD.

People form the core of an organization. Formation of company personnel, staffing.
Sage's reorganization includes a 40% workforce reduction and executive changes • Source: Shutterstock

More from Strategy

More from Business